Organoid drug screening report for a non-small cell lung cancer patient with EGFR gene mutation negativity: A case report and review of the literature
Patients with non-small cell lung cancer (NSCLC) who carry epidermal growth factor receptor (EGFR) mutations can benefit significantly from EGFR tyrosine kinase inhibitors (EGFR TKIs). However, it is unclear whether patients without EGFR mutations cannot benefit from these drugs. Patient-derived tum...
Main Authors: | Yuetian Pan, Hongshang Cui, Yongbin Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1109274/full |
Similar Items
-
Advances in lung cancer organoid research
by: JIA Zi-qi, WANG Yan-yu, WANG Ya-dong, BING Zhong-xing, LIANG Nai-xin, LI Shan-qing
Published: (2020-08-01) -
Therapeutic applications of three-dimensional organoid models in lung cancer
by: Chang Dong Yeo, et al.
Published: (2021-04-01) -
Rapid anticancer drug screening using patient-derived lung cancer organoids: a case report
by: Hyeong Jun Cho, et al.
Published: (2022-12-01) -
EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
by: Sho Takuma, MD, et al.
Published: (2022-01-01) -
Multiple synchronous primary lung adenocarcinomas with distinct epidermal growth factor receptor mutations: A case report
by: Matthew Siskin, et al.
Published: (2022-09-01)